Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...

A first-of-its-kind oral drug boosts muscle metabolism to improve blood sugar and body composition is now headed into larger ...

Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

While the WHO study saw reports of suicidal thoughts were slightly higher for semaglutide in particular, the warning applies ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

And Big Pharma’s not done cashing in on the weight-loss boom. Drugmakers are readying a new wave of next-level GLP-1 treatments, with several promising candidates in the pipeline. These experimental ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight ...

Novo, which in September said it secured Indian regulatory approval to import and sell Ozempic, on Thursday said it hoped to ...

GLP-1 medications have been a life-changing tool to help people manage their blood sugar and lose weight. But the most popular forms of these medications have a big drawback: You have to inject ...

A new oral GLP-1 receptor agonist, orforglipron, is revolutionizing weight management by offering a needle-free alternative ...

Next-generation pills and monthly injectables promise more choice, fewer side effects and broader health benefits.